Amgen UK Holdings Limited acquires major stake in Dark Blue Therapeutics
Published
Amgen UK Holdings Limited has joined the cap table of Dark Blue Therapeutics Ltd, acquiring 155,770,171 shares. This holding includes 80,307,384 Series A3, 46,163,560 Series A2, 21,299,227 Ordinary, and 8,000,000 Series A shares. The entry of this new shareholder follows the exit of all previous major institutional backers (confirmed in a filing on 5 June 2026).
BMS Strategic Portfolio Investments Holdings, Inc has departed the cap table, having previously held 45,575,547 shares. Other exiting shareholders include Oxford Science Enterprises PLC, which held 40,831,250 shares, and Evotec International GmbH, which held 25,963,013 shares. The Chancellor, Masters and Scholars of the University of Oxford also exited its position of 1,593,750 Ordinary shares.
Founded in 2020 and based in Oxford, Dark Blue Therapeutics develops precision oncology therapies. The company focuses on medicines that exploit cancer vulnerabilities, with a lead program targeting MLLT1/3 degraders for acute myeloid leukemia. Departing shareholder Oxford Science Enterprises PLC also backs Refeyn Ltd, Opsydia Limited, and Nucleome Therapeutics Limited. The University of Oxford is a shareholder in Refeyn Ltd, Covatic Ltd, and Navenio Limited. The transfer of shares from multiple departing entities to a single new entrant may signal a recent round or secondary transaction.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| Exited | BMS STRATEGIC PORTFOLIO INVESTMENTS HOLDINGS, INC | 45,575,547 | — | SERIES A2 23,075,547 SERIES A3 20,000,000 SERIES A 2,500,000 |
| Exited | OXFORD SCIENCE ENTERPRISES PLC | 40,831,250 | — | SERIES A3 35,000,000 SERIES A 3,000,000 ORDINARY 2,831,250 |
| Exited | EVOTEC INTERNATIONAL GMBH | 25,963,013 | — | SERIES A2 23,088,013 SERIES A 2,500,000 ORDINARY 375,000 |
| Exited | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD | 1,593,750 | — | ORDINARY 1,593,750 |
| New shareholder | AMGEN UK HOLDINGS LIMITED | 155,770,171 | — | SERIES A3 80,307,384 SERIES A2 46,163,560 ORDINARY 21,299,227 SERIES A 8,000,000 |
Current shareholders (1)
| Shareholder | Total shares | Share classes |
|---|---|---|
| AMGEN UK HOLDINGS LIMITED | 155,770,171 | ORDINARY 21,299,227 SERIES A 8,000,000 SERIES A2 46,163,560 SERIES A3 80,307,384 |
Contact the editorial team at [email protected]